BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CER-1236 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CER-1236\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06834282-2994@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:CER-1236: Phase 1 readout est. (NCT06834282)
DESCRIPTION:CER-1236\, phase 1\, Acute Myeloid Leukemia.\nStudy: CER-1236 i
 n Patients With Acute Myeloid Leukemia (AML)\, Myelodysplastic Syndrome (M
 DS)\, and Myelofibrosis (MF)\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cer-1236#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06834282
URL:https://assetmemo.bio/drug/cer-1236#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
